Therapeutic Antibody Half-Life Extension: Engineering Choices and Their Clinical Consequences. Translational Medicine & Therapeutics Journal, [S. l.], v. 5, n. 1, p. 74–82, 2026. DOI: 10.5281/zenodo.22649501. Disponível em: https://inkwise.org/index.php/TMTJ/article/view/124. Acesso em: 5 nov. 2026.